Last reviewed · How we verify
T-817MA
At a glance
| Generic name | T-817MA |
|---|---|
| Sponsor | FUJIFILM Toyama Chemical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD (PHASE2)
- Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202) (PHASE2)
- PK Study of T-817 in Subjects With Hepatic Impairment (PHASE1)
- Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T-817MA CI brief — competitive landscape report
- T-817MA updates RSS · CI watch RSS
- FUJIFILM Toyama Chemical Co., Ltd. portfolio CI